Implantable Wireless Systems: A Review of Potentials and Challenges

With the current advancement in micro-and nano-fabrication processes and the newly developed approaches, wireless implantable devices are now able to meet the demand for compact, self-powered, wireless, and long-lasting implantable devices for medical and health-care applications. The demonstrated fabrication advancement enabled the wireless implantable devices to overcome the previous limitations of electromagnetic-based wireless devices such as the high volume due to large antenna size and to overcome the tissue and bone losses related to the ultrasound implantable devices. Recent state-of-the-are wireless implantable devices can efficiently harvest electromagnetic energy and detect RF signals with minimum losses. Most of the current implanted devices are powered by batteries, which is not an ideal solution as these batteries need periodic charging and replacement. On the other hand, the implantable devices that are powered by energy harvesters are operating continuously, patient-friendly, and are easy to use. Future wireless implantable devices face a strong demand to be linked with IoT-based applications and devices with data visualization on mobile devices. This type of application requires additional units, which means more power consumption. Thus, the challenge here is to reduce the overall power consumption and increase the wireless power transfer efficiency. This chapter presents the state-of-the-art wireless power transfer techniques and approaches that are used to drive implantable devices. These techniques include inductive coupling, radiofrequency, ultrasonic, photovoltaic, and heat. The advantages and disadvantages of these approaches and techniques along with the challenges and limitations of each technique will be discussed. Furthermore, the performance parameters such as operating distance, energy harvesting efficiency, and size will be discussed and analyzed to introduce a comprehensive comparison. Finally, the recent advances in materials development and wireless communication strategies, are also discussed

Continuous macroscopic limit of a discrete stochastic model for interaction of living cells

In the development of multiscale biological models it is crucial to establish a connection between discrete microscopic or mesoscopic stochastic models and macroscopic continuous descriptions based on cellular density. In this paper a continuous limit of a two-dimensional Cellular Potts Model (CPM) with excluded volume is derived, describing cells moving in a medium and reacting to each other through both direct contact and long range chemotaxis. The continuous macroscopic model is obtained as a Fokker-Planck equation describing evolution of the cell probability density function. All coefficients of the general macroscopic model are derived from parameters of the CPM and a very good agreement is demonstrated between CPM Monte Carlo simulations and numerical solution of the macroscopic model. It is also shown that in the absence of contact cell-cell interactions, the obtained model reduces to the classical macroscopic Keller-Segel model. General multiscale approach is demonstrated by simulating spongy bone formation from loosely packed mesenchyme via the intramembranous route suggesting that self-organizing physical mechanisms can account for this developmental process.Comment: 4 pages, 3 figure

The pulsating DA white dwarf star EC 14012-1446: results from four epochs of time-resolved photometry

The pulsating DA white dwarfs are the coolest degenerate stars that undergo self-driven oscillations. Understanding their interior structure will help to understand the previous evolution of the star. To this end, we report the analysis of more than 200 h of time-resolved CCD photometry of the pulsating DA white dwarf star EC 14012-1446 acquired during four observing epochs in three different years, including a coordinated three-site campaign. A total of 19 independent frequencies in the star's light variations together with 148 combination signals up to fifth order could be detected. We are unable to obtain the period spacing of the normal modes and therefore a mass estimate of the star, but we infer a fairly short rotation period of 0.61 +/- 0.03 d, assuming the rotationally split modes are l=1. The pulsation modes of the star undergo amplitude and frequency variations, in the sense that modes with higher radial overtone show more pronounced variability and that amplitude changes are always accompanied by frequency variations. Most of the second-order combination frequencies detected have amplitudes that are a function of their parent mode amplitudes, but we found a few cases of possible resonantly excited modes. We point out the complications in the analysis and interpretation of data sets of pulsating white dwarfs that are affected by combination frequencies of the form f_A+f_B-f_C intruding into the frequency range of the independent modes.Comment: 14 pages, 6 figures, 6 tables. MNRAS, in pres

Heat Shock Protein 70 Prevents both Tau Aggregation and the Inhibitory Effects of Preexisting Tau Aggregates on Fast Axonal Transport

Aggregation and accumulation of the microtubule-associated protein tau are associated with cognitive decline and neuronal degeneration in Alzheimer's disease and other tauopathies. Thus, preventing the transition of tau from a soluble state to insoluble aggregates and/or reversing the toxicity of existing aggregates would represent a reasonable therapeutic strategy for treating these neurodegenerative diseases. Here we demonstrate that molecular chaperones of the heat shock protein 70 (Hsp70) family are potent inhibitors of tau aggregation in vitro, preventing the formation of both mature fibrils and oligomeric intermediates. Remarkably, addition of Hsp70 to a mixture of oligomeric and fibrillar tau aggregates prevents the toxic effect of these tau species on fast axonal transport, a critical process for neuronal function. When incubated with preformed tau aggregates, Hsp70 preferentially associated with oligomeric over fibrillar tau, suggesting that prefibrillar oligomeric tau aggregates play a prominent role in tau toxicity. Taken together, our data provide a novel molecular basis for the protective effect of Hsp70 in tauopathies

Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases

© The Author(s), 2011. This article is distributed under the terms of the Creative Commons Attribution License. The definitive version was published in Journal of Neuroscience 31 (2011): 9858-9868, doi:10.1523/JNEUROSCI.0560-11.2011.Aggregated filamentous forms of hyperphosphorylated tau (a microtubule-associated protein) represent pathological hallmarks of Alzheimer's disease (AD) and other tauopathies. While axonal transport dysfunction is thought to represent a primary pathogenic factor in AD and other neurodegenerative diseases, the direct molecular link between pathogenic forms of tau and deficits in axonal transport remain unclear. Recently, we demonstrated that filamentous, but not soluble, forms of wild-type tau inhibit anterograde, kinesin-based fast axonal transport (FAT) by activating axonal protein phosphatase 1 (PP1) and glycogen synthase kinase 3 (GSK3), independent of microtubule binding. Here, we demonstrate that amino acids 2–18 of tau, comprising a phosphatase-activating domain (PAD), are necessary and sufficient for activation of this pathway in axoplasms isolated from squid giant axons. Various pathogenic forms of tau displaying increased exposure of PAD inhibited anterograde FAT in squid axoplasm. Importantly, immunohistochemical studies using a novel PAD-specific monoclonal antibody in human postmortem tissue indicated that increased PAD exposure represents an early pathogenic event in AD that closely associates in time with AT8 immunoreactivity, an early marker of pathological tau. We propose a model of pathogenesis in which disease-associated changes in tau conformation lead to increased exposure of PAD, activation of PP1-GSK3, and inhibition of FAT. Results from these studies reveal a novel role for tau in modulating axonal phosphotransferases and provide a molecular basis for a toxic gain-of-function associated with pathogenic forms of tau.This work was supported by NIH Grants T32 AG020506-07 (N.M.K.); AG09466 (L.I.B.); and NS23868, NS23320, and NS41170 (S.T.B.); as well as 2007/2008 MBL Summer Research Fellowships and an ALS/CVS Therapy Alliance grant (G.M.)

Extra corporal membrane oxygenation in general thoracic surgery: a new single veno-venous cannulation

Extracorporeal membrane oxygenation (ECMO) is used in severe respiratory failure to maintain adequate gas exchange. So far, this technique has not been commonly used in general thoracic surgery. We present a case using ECMO for peri-operative airway management for pulmonary resection, using a novel single-site, internal jugular, veno-venous ECMO cannula

Behavioural support and nicotine replacement therapy for Smokeless Tobacco cessation:Protocol for a pilot randomised-controlled multi-country trial

Background Smokeless tobacco (ST) is consumed globally by more than 350 million people, with approximately 85% of all users based in South and Southeast Asia. In this region, ST products are cheap and easily accessible. Evidence-based interventions to people quit ST use are lacking. This study aims to test the feasibility of conducting a future definitive trial of ST cessation, using a culturally adapted behavioural intervention, and/or nicotine replacement therapy (NRT) in three South Asian countries. Methods We will conduct a factorial design, randomised-controlled pilot trial in Bangladesh, India and Pakistan. Daily ST users will be recruited from primary health care settings in Dhaka, Noida and Karachi. Participants will be individually randomised to receive intervention A (4 or 6 mg NRT chewing gum for 8-weeks), intervention B (BISCA: face-to-face behavioural support for ST cessation), a combination of interventions A and B or usual care (Very Brief Advice - VBA). The participants will provide demographic and ST use related data at baseline, and at 6, 12 and 26 weeks of follow-up. Salivary cotinine samples will be collected at baseline and 26 weeks. The analyses will undertake an assessment of the feasibility of recruitment, randomisation, data collection and participant retention, as well as the feasibility of intervention delivery. We will also identify potential cessation outcomes to inform the main trial, understand the implementation, context and mechanisms of impact through a process evaluation and, thirdly, establish health resource use and impact on the quality of life through health economic data. Discussion The widespread and continued use of ST products in South Asia is consistent with a high rate of associated diseases and negative impact on the quality of life. The identification of feasible, effective and cost-effective interventions for ST is necessary to inform national and regional efforts to reduce ST use at the population level. The findings of this pilot trial will inform the development of larger trials for ST cessation among South Asian users, with relevance to wider regions and populations having high rates of ST use. Trial registration ISRCTN identifier 6510939